Role of lymph node dissection and splenectomy in node-positive gastric carcinoma

Y. Adachi, T. Kamakura, M. Mori, Y. Maehara, K. Sugimachi

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Background. In gastric carcinoma the relationship between survival of patients and degree of lymph node dissection is still controversial and there is no agreement about the efficacy of extended lymph node dissection and splenectomy. Methods. Long-term results after surgery were statistically analyzed in 240 patients who underwent curative gastrectomy with lymph node dissection for node-positive gastric carcinoma from 1975 to 1990. Results. The survival of patients was not significantly different among R1, R2, and R3 dissections, with the 10-year survival rate being 57%, 50%, and 44%, respectively. The survival rate was also not different between R2 and R3, even when the cases were stratified by the level of lymph node metastasis (N1, 66% vs 58%; N2, 28% vs 31%). The survival of patients was not significantly different between cases treated without splenectomy and those treated with splenectomy, with 10-year survival rates being 47% and 26%, respectively. The survival rate was also not different between non- splenectomy- and splenectomy-treated cases, even when the patients were compared in the same level of lymph node metastasis (N1, 60% vs 45%; N2, 23% vs 11%). Conclusions. In cases of curative gastrectomy the survival time of patients was not influenced by the level of lymph node dissection and splenectomy. For the treatment of node-positive gastric carcinoma (N1, N2) the long-term efficacy of R3 dissection and splenectomy seems limited.

Original languageEnglish
Pages (from-to)837-841
Number of pages5
JournalSurgery
Volume116
Issue number5
Publication statusPublished - Jan 1 1994

Fingerprint

Splenectomy
Lymph Node Excision
Stomach
Carcinoma
Survival Rate
Survival
Gastrectomy
Dissection
Lymph Nodes
Neoplasm Metastasis

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Adachi, Y., Kamakura, T., Mori, M., Maehara, Y., & Sugimachi, K. (1994). Role of lymph node dissection and splenectomy in node-positive gastric carcinoma. Surgery, 116(5), 837-841.

Role of lymph node dissection and splenectomy in node-positive gastric carcinoma. / Adachi, Y.; Kamakura, T.; Mori, M.; Maehara, Y.; Sugimachi, K.

In: Surgery, Vol. 116, No. 5, 01.01.1994, p. 837-841.

Research output: Contribution to journalArticle

Adachi, Y, Kamakura, T, Mori, M, Maehara, Y & Sugimachi, K 1994, 'Role of lymph node dissection and splenectomy in node-positive gastric carcinoma', Surgery, vol. 116, no. 5, pp. 837-841.
Adachi Y, Kamakura T, Mori M, Maehara Y, Sugimachi K. Role of lymph node dissection and splenectomy in node-positive gastric carcinoma. Surgery. 1994 Jan 1;116(5):837-841.
Adachi, Y. ; Kamakura, T. ; Mori, M. ; Maehara, Y. ; Sugimachi, K. / Role of lymph node dissection and splenectomy in node-positive gastric carcinoma. In: Surgery. 1994 ; Vol. 116, No. 5. pp. 837-841.
@article{deea49f2c5654e1891cd5f8dec3b708a,
title = "Role of lymph node dissection and splenectomy in node-positive gastric carcinoma",
abstract = "Background. In gastric carcinoma the relationship between survival of patients and degree of lymph node dissection is still controversial and there is no agreement about the efficacy of extended lymph node dissection and splenectomy. Methods. Long-term results after surgery were statistically analyzed in 240 patients who underwent curative gastrectomy with lymph node dissection for node-positive gastric carcinoma from 1975 to 1990. Results. The survival of patients was not significantly different among R1, R2, and R3 dissections, with the 10-year survival rate being 57{\%}, 50{\%}, and 44{\%}, respectively. The survival rate was also not different between R2 and R3, even when the cases were stratified by the level of lymph node metastasis (N1, 66{\%} vs 58{\%}; N2, 28{\%} vs 31{\%}). The survival of patients was not significantly different between cases treated without splenectomy and those treated with splenectomy, with 10-year survival rates being 47{\%} and 26{\%}, respectively. The survival rate was also not different between non- splenectomy- and splenectomy-treated cases, even when the patients were compared in the same level of lymph node metastasis (N1, 60{\%} vs 45{\%}; N2, 23{\%} vs 11{\%}). Conclusions. In cases of curative gastrectomy the survival time of patients was not influenced by the level of lymph node dissection and splenectomy. For the treatment of node-positive gastric carcinoma (N1, N2) the long-term efficacy of R3 dissection and splenectomy seems limited.",
author = "Y. Adachi and T. Kamakura and M. Mori and Y. Maehara and K. Sugimachi",
year = "1994",
month = "1",
day = "1",
language = "English",
volume = "116",
pages = "837--841",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Role of lymph node dissection and splenectomy in node-positive gastric carcinoma

AU - Adachi, Y.

AU - Kamakura, T.

AU - Mori, M.

AU - Maehara, Y.

AU - Sugimachi, K.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Background. In gastric carcinoma the relationship between survival of patients and degree of lymph node dissection is still controversial and there is no agreement about the efficacy of extended lymph node dissection and splenectomy. Methods. Long-term results after surgery were statistically analyzed in 240 patients who underwent curative gastrectomy with lymph node dissection for node-positive gastric carcinoma from 1975 to 1990. Results. The survival of patients was not significantly different among R1, R2, and R3 dissections, with the 10-year survival rate being 57%, 50%, and 44%, respectively. The survival rate was also not different between R2 and R3, even when the cases were stratified by the level of lymph node metastasis (N1, 66% vs 58%; N2, 28% vs 31%). The survival of patients was not significantly different between cases treated without splenectomy and those treated with splenectomy, with 10-year survival rates being 47% and 26%, respectively. The survival rate was also not different between non- splenectomy- and splenectomy-treated cases, even when the patients were compared in the same level of lymph node metastasis (N1, 60% vs 45%; N2, 23% vs 11%). Conclusions. In cases of curative gastrectomy the survival time of patients was not influenced by the level of lymph node dissection and splenectomy. For the treatment of node-positive gastric carcinoma (N1, N2) the long-term efficacy of R3 dissection and splenectomy seems limited.

AB - Background. In gastric carcinoma the relationship between survival of patients and degree of lymph node dissection is still controversial and there is no agreement about the efficacy of extended lymph node dissection and splenectomy. Methods. Long-term results after surgery were statistically analyzed in 240 patients who underwent curative gastrectomy with lymph node dissection for node-positive gastric carcinoma from 1975 to 1990. Results. The survival of patients was not significantly different among R1, R2, and R3 dissections, with the 10-year survival rate being 57%, 50%, and 44%, respectively. The survival rate was also not different between R2 and R3, even when the cases were stratified by the level of lymph node metastasis (N1, 66% vs 58%; N2, 28% vs 31%). The survival of patients was not significantly different between cases treated without splenectomy and those treated with splenectomy, with 10-year survival rates being 47% and 26%, respectively. The survival rate was also not different between non- splenectomy- and splenectomy-treated cases, even when the patients were compared in the same level of lymph node metastasis (N1, 60% vs 45%; N2, 23% vs 11%). Conclusions. In cases of curative gastrectomy the survival time of patients was not influenced by the level of lymph node dissection and splenectomy. For the treatment of node-positive gastric carcinoma (N1, N2) the long-term efficacy of R3 dissection and splenectomy seems limited.

UR - http://www.scopus.com/inward/record.url?scp=0028034784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028034784&partnerID=8YFLogxK

M3 - Article

C2 - 7940186

AN - SCOPUS:0028034784

VL - 116

SP - 837

EP - 841

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 5

ER -